title: Contractile failure in chronic doxorubicin-induced cardiomyopathy.
abstract: The mechanisms for the progression of the anthracycline-induced cardiomyopathy to contractile failure has not been defined. In vitro, doxorubicin (DOX) appears to modify calcium-mediated excitation-contraction coupling, which depresses cardiac contractility. This study characterizes the onset of contractile failure associated with the development of DOX-induced cardiomyopathy. Rabbits were treated with DOX (1 mg/kg i.v. twice weekly, 12-18 doses; DOX-treated group) and compared with a pair-fed Control group infuse with saline vehicle. The severity of the cardiomyopathy was determined by numerically-scored histopathology. Myocardial contractility was determined in thin fiber bundles from right ventricular (RV) papillary muscles and left atria that were removed and mounted on a force transducer in oxygenated Krebs-bicarbonate buffer (pH=7.4 at 30 degrees C) to record the amplitude (DT) and maximum rate (+dT/dt ) of isometric tension. Myofibrillar and calcium loading properties were determined by the calcium and caffeine-activated tension responses respectively in chemically-permeabilized fibers. With the onset of the cardiomyopathy (score <2) DT at low frequency (0.5 Hz) was depressed (0.61+/-0.01 mN/mg; n=14) compared to Control (0.93+/-0.09 mN/mg; n=15). Contractility at higher rates (1 Hz) was not different in this DOX-treated and Control groups. Maximum calcium and caffeine-activated force and the pCa to half-maximum force of permeabilized fibers were comparable in DOX-treated and Control groups. The loss of contractility of the DOX-treated group was related to reduction in sarcoplasmic reticulum calcium release channel density, as determined by Bmax for 3H-ryanodine binding in cardiac microsomal membrane fraction. Post-rest potentiation of contractility, as well as frequency-dependent (0.25-1.5 Hz) and post-extrasystolic potentiation of contractility were preserved in the DOX-treated group. In vitro, DOX depressed post-rest potentiation of contractility. Thus, the onset of contractile failure of the DOX-induced cardiomyopathy is characterized by effects consistent with disordered calcium-mediated excitation-contraction coupling and these effects are qualitatively different than in vitro effects of DOX.
authors.affiliation: Department of Pediatrics, University of South Florida College of Medicine, Tampa, FL 33701-4827, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Boucek
authors.forename: D A
authors.initials: DA
authors.lastname: Dodd
authors.forename: J B
authors.initials: JB
authors.lastname: Atkinson
authors.forename: N
authors.initials: N
authors.lastname: Oquist
authors.forename: R D
authors.initials: RD
authors.lastname: Olson
mesh_terms: D000818:Animals; D015220:Calcium Channels / Q000378:metabolism; D009202:Cardiomyopathies / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D004317:Doxorubicin; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D011817:Rabbits; D012433:Ryanodine / Q000378:metabolism / Q000494:pharmacology
chemical_list: D015220:Calcium Channels; D012433:Ryanodine; D004317:Doxorubicin